Systemische Sklerodermie

Lernziele

Kenntnisse über:

Pathogenese der systemischen Sklerodermie Einteilung Diagnostik Therapie neue Therapieaussichten DNSS (Deutsches Netzwerk für systemische Sklerodermie)

Literatur

• 1 Denton C P, Black C M. Targeted therapy comes of age in scleroderma.  Trends Immunol. 2005;  26 596-602
• 2 Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events.  Ann Med. 2007;  39 42-53
• 3 Flavahan N A, Flavahan S, Mitra S et al. The vasculopathy of Raynaud’s phenomenon and scleroderma.  Rheum Dis Clin North Am. 2003;  29 275-291
• 4 Medsger T A, Masi A T. Epidemiology of systemic sclerosis (scleroderma).  Ann Intern Med. 1971;  74 714-721
• 5 Denton C P, Black C M. Scleroderma and related disorders: therapeutic aspects.  Baillieres Best Pract Res Clin Rheumatol. 2000;  14 17-35
• 6 Hunzelmann N, Genth E, Krieg T et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement.  Rheumatology (Oxford). 2008;  47 1185-1192
• 7 Cutolo M, Sulli A, Secchi M E et al. The contribution of capillaroscopy to the differential diagnosis of connective autoimmune diseases.  Best Pract Res Clin Rheumatol. 2007;  21 1093-1108
• 8 Ranque B, Authier F J, Berezne A et al. Systemic sclerosis-associated myopathy.  Ann N Y Acad Sci. 2007;  1108 268-282
• 9 Kleinert S, Tony H P, Kneitz C. Systemic sclerosis.  Internist. 2006;  47 1051-1061
• 10 Hachulla E, Gressin V, Guillevin  et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study.  Arthritis Rheum. 2005;  52 3792-3800
• 11 Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.  Ann Rheum Dis. 2003;  62 1088-1093
• 12 Grünig E, Barner A, Bell M et al. Nicht-invasive Diagnostik der pulmonalen Hypertonie: ESC/ERS-Leitlinien mit Kommentierung der Kölner Konsensus-Konferenz 2010.  Dtsch Med Wochenschr. 2010;  135 (Suppl. 3) 67-77
• 13 Pignone A, Mori F, Pieri F et al. Exercise Doppler echocardiography identifies preclinic asymptomatic pulmonary hypertension in systemic sclerosis.  Ann N Y Acad Sci. 2007;  1108 291-304
• 14 Dumitrescu D, Oudiz R J, Karpouzas G et al. Developing Pulmonary Vasculopathy in Systemic Sclerosis, Detected with Non-Invasive Cardiopulmonary Exercise Testing.  PLoS One. 2010;  5 e14293
• 15 Rhew E Y, Barr W G. Scleroderma renal crisis.  Curr Rheumatol Rep. 2004;  6 129-136
• 16 Seiberlich B, Hunzelmann N, Krieg T, Weber M, Schulze-Lohoff E. Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity.  Clinical Nephrology. 2008;  70 110-117
• 17 Hunzelmann N, Genth E, Krieg T et al. Organspezifische Diagnostik von Patienten mit systemischer Sklerodermie. Empfehlungen des Deutschen Netzwerkes für Systemische Sklerodermie (DNSS).  Z Rheumatol. 2008;  67 334-340
• 18 Steen V D, Medsger T A. Changes in causes of death in systemic sclerosis, 1972 – 2002.  Ann Rheum Dis. 2007;  66 940-944
• 19 Kowal-Bielecka O, Distler O. Use of methotrexate in patients with scleroderma and mixed connective tissue disease.  Clin Exp Rheumatol. 2010;  28 (Suppl. 61) 160-163
• 20 Steen V D, Medsger T A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.  Arthritis Rheum. 1998;  41 1613-1619
• 21 Steen V, Denton C P, Pope J E et al. Digital ulcers: overt vascular disease in systemic sclerosis.  Rheumatology (Oxford). 2009;  48 (Suppl. 3) 19-24
• 22 Pope J, Fenlon D, Thompson A et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis.  Cochrane Database Syst Rev. 2000;  2 CD000953
• 23 Matucci-Cerinic M, Denton C P, Furst D E et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.  Ann Rheum Dis. 2011;  70 32-38
• 24 Denton C P, Black C M. Scleroderma and related disorders: therapeutic aspects.  Baillieres Best Pract Res Clin Rheumatol. 2000;  14 17-35
• 25 Allanore Y, Avouac J, Wipff J et al. New therapeutic strategies in the management of systemic sclerosis.  Expert Opin Pharmacother. 2007;  8 607-615
• 26 Tashkin D P, Elashoff R, Clements P J et al. Cyclophosphamide versus placebo in scleroderma lung disease.  N Engl J Med. 2006;  354 2655-2666
• 27 Steen V D, Constantino J P, Shapiro A P et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin-converting enzyme (ACE) inhibitors.  Ann Intern Med. 1990;  113 352-357
• 28 Steen V D, Medsger T A. Long-term outcomes of scleroderma renal crisis.  Ann Intern Med. 2000;  133 600-603
• 29 Ghofrani H A, Distler O, Gerhardt F et al. Therapie der pulmonal arteriellen Hypertonie (PAH): Empfehlungen der Kölner Konsensus-Konferenz 2010.  Dtsch Med Wochenschr. 2010;  135 (Suppl. 3) 87-101
• 30 Barst R J, Gibbs S R, Ghofrani H A et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension.  J Am Coll Cardiol. 2009;  54 (Suppl. 1) 78-84
• 31 Galiè N, Hoeper M M, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension.  Eur Heart J. 2009;  30 2493-2537